MedTrace Logo

Phase I Study PK Study With OXP005 and Naprosyn

NCT02351024 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2015-04-01

No results posted yet for this study

Summary

The Sponsor is developing a new form of naproxen (the study drug, OXP005), for the potential treatment of rheumatic and painful conditions. The study will compare the study drug to an already marketed formulation of prescription strength naproxen (Naprosyn® the reference product) by looking at how a single dose of the drug is taken up by the body. The safety and tolerability of the drug will also be assessed.

Conditions

  • Pharmacokinetics

Interventions

DRUG

OXP005

DRUG

Naprosyn®

Sponsors & Collaborators

  • Oxford Pharmascience Ltd

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02351024 on ClinicalTrials.gov